---
schema_version: "secwatch.filing_event.v1"
accession: "0001724521-24-000050"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2024-02-21T23:59:59+00:00"
generated_at: "2026-06-05T22:11:45.191530+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcus Q4 net loss $81M; cash to $1.2B after Gilead; streamlines TIGIT program; casdatifan shows promise

## Summary
- Net loss of $81M in Q4 2023 ($307M full year); revenue $31M Q4 2023 vs $34M Q4 2022.
- Pro forma cash $1.2B after $320M equity investment from Gilead in Jan 2024; funding into 2027.
- Discontinued ARC-10 Phase 3 in PD-L1-high NSCLC; accelerating STAR-121; planning STAR-131 in perioperative NSCLC.
- Casdatifan (HIF-2a) Phase 1 data: 20 mg dose achieved similar EPO suppression as 120 mg belzutifan; no DLTs.
- Quemliclustat in pancreatic cancer: median OS 15.7 months in pooled ARC-8 analysis; Phase 3 planned early 2025.

## SEC filing metadata
- accession: 0001724521-24-000050
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2024-02-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000050/0001724521-24-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000050/rcus-20240221.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001724521-24-000050
- JSON: https://secwatch.observer/filing/0001724521-24-000050.json
- Plain text: https://secwatch.observer/filing/0001724521-24-000050.txt

## Key facts
- Earnings Releases
  Arcus Biosciences, Inc. reported financial results for the three months and full year ended December 31, 2023.
  - Period: the three months and full year ended December 31, 2023
  - Result: reported results
  source text: On February 21, 2024, Arcus Biosciences, Inc. issued a press release announcing its financial results for the three months and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000050/0001724521-24-000050-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.